LEXINGTON, Mass.–(BUSINESS WIRE)–Jan. 24, 2019-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated the second Phase 1 clinical trial with CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 single-ascending dose trial will evaluate the safety, tolerability, and pharmacokinetic profile of CTP-692 in healthy volunteers.
“For decades all approved schizophrenia drugs have acted predominantly by modulation of dopamine, or dopamine and serotonin receptors. By activating glutamatergic pathways as an NMDA co-agonist, CTP-692 has the potential to be a safe and effective new adjunctive treatment for schizophrenia, and treat positive and negative symptoms and cognitive dysfunction,” stated Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals, Inc